Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
When navigating the FDA regulatory landscape for medical devices, understanding the distinction between General Controls and Special Controls is fundamental. What are Class II Special Controls, and ho...
When planning budgets for EU market access in 2026, non-EU manufacturers often ask about the cost of a REACH Only Representative (OR). However, providing a single figure is challenging, as the total c...
When preparing a premarket submission for a connected medical device, such as a Class II Software as a Medical Device (SaMD) or a networked patient monitor, how can sponsors construct a comprehensive ...
For manufacturers developing novel in vitro diagnostic (IVD) assays, what are the key regulatory distinctions between using commercially distributed Analyte Specific Reagents (ASRs) as components vers...
When developing a premarket submission for a Class II medical device, how should a sponsor approach the validation and documentation for an adaptive algorithm, such as one used in a retinal diagnostic...
With global Extended Producer Responsibility (EPR) and Waste Electrical and Electronic Equipment (WEEE) regulations for electronic medical devices becoming increasingly stringent and fragmented ahead ...
As medical device manufacturers prepare for significant updates to WEEE and EPR frameworks across the EU, with major changes anticipated around 2026, what is a comprehensive framework for selecting an...
For manufacturers of medical devices containing batteries, navigating the expansion of Extended Producer Responsibility (EPR) laws into the United States presents a new compliance challenge. With Cali...
As regulatory expectations and consensus standards for biocompatibility periodically evolve, how can sponsors of medical devices—for instance, a Class II implantable sensor with long-term tissue conta...
When planning for future medical device submissions, how should a manufacturer approach the topic of evolving testing standards, such as biocompatibility? Rather than focusing on a single, universal f...
With significant updates to global biocompatibility standards anticipated around 2026, what strategic steps should medical device manufacturers take now to prepare their biological safety evaluation s...
For non-UK medical device manufacturers, what are the key requirements and responsibilities associated with appointing a UK Responsible Person (UKRP) to maintain compliance and market access in Great ...
As the UK continues to establish its post-Brexit medical device regulatory framework, non-UK manufacturers must navigate the evolving responsibilities of the UK Responsible Person (UKRP). With future ...
With the evolving post-Brexit regulatory landscape for medical devices in Great Britain, the role of the UK Responsible Person (UKRP) has become a critical compliance function for manufacturers based ...
For medical device manufacturers located outside the United States, selecting an FDA U.S. Agent is a mandatory step for market entry, but the strategic implications of this choice are often underestim...
For manufacturers of Class II in vitro diagnostic (IVD) devices, demonstrating a reasonable assurance of safety and effectiveness often extends beyond meeting General Controls. When FDA determines tha...
When developing a cybersecurity threat model for a connected medical device, such as a Class II Software as a Medical Device (SaMD) that communicates with a hospital network, what are the essential co...
Given the evolving global landscape for environmental compliance, with significant updates to Waste from Electrical and Electronic Equipment (WEEE) and Extended Producer Responsibility (EPR) regulatio...
With significant updates to the ISO 10993 series anticipated to be harmonized around 2026, how can medical device manufacturers strategically prepare their biocompatibility programs to ensure complian...
When a key consensus standard for biocompatibility is updated, how should medical device sponsors adjust their testing strategy for upcoming premarket submissions? Navigating the transition period bet...